Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 CAD | +1.06% | +2.80% | +21.01% |
04-08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
03-14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.01% | 110M | |
+17.76% | 71.72B | |
-2.19% | 24.29B | |
+7.71% | 8.31B | |
-19.61% | 8.22B | |
+1.47% | 8.16B | |
+5.56% | 4.76B | |
+15.41% | 4.31B | |
-0.87% | 4.1B | |
+23.20% | 3.78B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million